| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
SHORT REPORT |
1 Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital, Tokyo 189-8511, Japan
2 Radiology, Tokyo Metropolitan Tama Geriatric Hospital
3 Second Department of Internal Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
Correspondence to:
Correspondence to:
Dr H Nagayama
Second Department of Internal Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan; nagaya2{at}attglobal.net
ABSTRACT
Aim: To evaluate the reliability of [123I]meta-iodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson’s disease (PD).
Patients/Methods: A series of 391 outpatients showing one or more parkinsonian-like symptoms was longitudinally followed up for accurate clinical diagnosis. MIBG scintigraphy was performed in the patients and 10 normal controls of similar age. The heart to mediastinum uptake ratio was calculated in each person, and the values were considered abnormal if they were greater than two standard deviations below the control mean.
Results: MIBG uptake was decreased in most patients with PD (87.7%), and was seen in all advanced cases with Hohen-Yahr stage III or more; the sensitivity and specificity of scintigraphy for detecting PD were 87.7% and 37.4%, respectively. Surprisingly, over half of the patients without PD (66.5%) also exhibited low uptake, resulting in considerable overlap in the ratios between PD and the other disorders.
Conclusion: MIBG scintigraphy is a sensitive, but not specific, test for PD. Low MIBG uptake does not necessarily indicate PD, but is essential for diagnosing advanced PD.
Abbreviations: CVD, cerebrovascular disease; DLB, dementia with Lewy bodies; H/M, heart to mediastinum; HY, Hohen-Yahr; MIBG, meta-iodobenzylguanidine; MSA, multiple system atrophy; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; SDAT, senile dementia of Alzheimer type
Keywords: Parkinson’s disease; myocardial scintigraphy; meta-iodobenzylguanidine
This article has been cited by other articles:
|
|
 |
|
  S. Gilman, G. K. Wenning, P. A. Low, D. J. Brooks, C. J. Mathias, J. Q. Trojanowski, N. W. Wood, C. Colosimo, A. Durr, C. J. Fowler, et al. Second consensus statement on the diagnosis of multiple system atrophy Neurology, August 26, 2008; 71(9): 670 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kumazawa, H. Tomiyama, Y. Li, Y. Imamichi, M. Funayama, H. Yoshino, F. Yokochi, T. Fukusako, Y. Takehisa, K. Kashihara, et al. Mutation Analysis of the PINK1 Gene in 391 Patients With Parkinson Disease Arch Neurol, June 1, 2008; 65(6): 802 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Hinkle, J. V. Dura, R. S. Morosco, and M. C. Nahata Extended stability of iobenguane under simulated clinical conditions Am. J. Health Syst. Pharm., January 15, 2008; 65(2): 142 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Raffel, R. A. Koeppe, R. Little, C.-N. Wang, S. Liu, L. Junck, M. Heumann, and S. Gilman PET Measurement of Cardiac and Nigrostriatal Denervation in Parkinsonian Syndromes J. Nucl. Med., November 1, 2006; 47(11): 1769 - 1777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P H Lee, J S Kim, D H Shin, S-N Yoon, and K Huh Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 372 - 374. [Abstract] [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
